Or Eisenberg Buys 250,000 Shares of NeuroSense Therapeutics (NASDAQ:NRSN) Stock

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) CFO Or Eisenberg bought 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were purchased at an average cost of $0.80 per share, for a total transaction of $200,000.00. Following the purchase, the chief financial officer owned 1,504,050 shares in the company, valued at $1,203,240. This represents a 19.94% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

NeuroSense Therapeutics Price Performance

Shares of NeuroSense Therapeutics stock opened at $0.80 on Friday. The business has a 50-day moving average of $0.78 and a 200 day moving average of $0.85. NeuroSense Therapeutics Ltd. has a 12 month low of $0.63 and a 12 month high of $2.52. The stock has a market capitalization of $26.20 million, a price-to-earnings ratio of -1.49 and a beta of 1.56.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NRSN. Yorkville Advisors Global LP purchased a new stake in NeuroSense Therapeutics during the 4th quarter worth about $77,000. Squarepoint Ops LLC boosted its stake in shares of NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after buying an additional 45,450 shares during the period. Jane Street Group LLC purchased a new position in shares of NeuroSense Therapeutics in the 2nd quarter valued at about $54,000. Finally, Two Sigma Investments LP acquired a new position in shares of NeuroSense Therapeutics during the third quarter worth about $26,000. 1.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently commented on NRSN. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research note on Friday, May 8th. Roth Mkm started coverage on shares of NeuroSense Therapeutics in a research note on Tuesday, March 10th. They set a “buy” rating and a $3.00 target price on the stock. Finally, D. Boral Capital reiterated a “buy” rating and set a $14.00 target price on shares of NeuroSense Therapeutics in a report on Wednesday, April 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.